{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:56:41Z","timestamp":1793120201334,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Xinjiang Corps Natural Science Support Project","award":["2024ZD073"],"award-info":[{"award-number":["2024ZD073"]}]},{"name":"Xinjiang Corps Natural Science Support Project","award":["2024DA044"],"award-info":[{"award-number":["2024DA044"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82360606"],"award-info":[{"award-number":["82360606"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The First Affiliated Hospital of Shihezi University Project","award":["BS2024002"],"award-info":[{"award-number":["BS2024002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer (PCa) is a globally prevalent malignancy in males and is imposing an increasing epidemiological burden. The androgen receptor (AR) signalling axis is fundamentally implicated in PCa tumorigenesis and disease progression. Although androgen deprivation therapy (ADT) elicits transient therapeutic responses in the majority of cases, progression to castration-resistant prostate cancer (CRPC) remains an almost universal clinical trajectory. Dysregulated lipid homeostasis, manifesting as intracellular lipid deposition, has been mechanistically linked to CRPC pathogenesis and therapeutic failure under enzalutamide regimens. However, effective strategies to mitigate lipid accumulation in PCa remain elusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>STARD4, a key gene involved in lipid metabolism, was identified as functionally significant in PCa through integrated bioinformatics analysis of public databases. RT\u2012qPCR, western blot analysis, and IHC staining were performed to evaluate STARD4 expression, while Kaplan\u2013Meier survival analysis, Gleason score, and tumor stage were performed to assess its clinical significance in PCa. The biological functions of STARD4 and its contribution to enzalutamide resistance were elucidated through in vitro and in vivo experiments. The effect of STARD4 on abnormal lipid accumulation in PCa cells was evaluated by Oil Red O (ORO) staining, while its impact on endoplasmic reticulum (ER) stress was assessed through ER-tracking imaging and transmission electron microscopy (TEM). Mechanistic exploration involves a combination of techniques, including RNA-seq analysis, Gene ontology analysis, coimmunoprecipitation (Co-IP), and GST pull-down assay, to analyse the interactions and potential mechanisms involving STARD4, AR, and E3 ubiquitin ligase UBE4B.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this study, we observed that STARD4 expression was markedly reduced in PCa tissues and was correlated with an adverse prognosis. STARD4 overexpression inhibited PCa cell proliferation, migration, and lipid accumulation while promoting apoptosis through ER stress. Mechanistically, STARD4 enhanced the interaction between UBE4B and AR, facilitating AR ubiquitination and degradation and thus suppressing AR signalling. Additionally, the upregulation of STARD4 expression enhanced sensitivity to enzalutamide in resistant cells by diminishing lipid accumulation and inhibiting the AR signalling pathway. In summary, STARD4 functions as a tumour suppressor in PCa by regulating cholesterol metabolism and modulating AR signalling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings identify STARD4 as a promising therapeutic target for reversing enzalutamide resistance in PCa while also providing novel insights for future research on lipid metabolism within the tumour microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03600-7","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T17:04:38Z","timestamp":1764695078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["STARD4 suppresses tumorigenesis and attenuates enzalutamide resistance via lipid metabolic reprogramming and AR stabilization in prostate cancer"],"prefix":"10.1186","volume":"44","author":[{"given":"Yi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinzhang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"1","key":"3600_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"3600_CR2","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27(17):5730.","journal-title":"Molecules"},{"issue":"2","key":"3600_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bph.15300","volume":"178","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, et al. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021;178(2):239\u201361.","journal-title":"Br J Pharmacol"},{"issue":"11","key":"3600_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41585-019-0237-8","volume":"16","author":"SY Ku","year":"2019","unstructured":"Ku SY, Gleave ME, Beltran H. Towards precision oncology in advanced prostate cancer. Nat Rev Urol. 2019;16(11):645\u201354.","journal-title":"Nat Rev Urol"},{"issue":"13","key":"3600_CR5","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187\u201397.","journal-title":"N Engl J Med"},{"issue":"10","key":"3600_CR6","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","volume":"41","author":"C Buttigliero","year":"2015","unstructured":"Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M, et al. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev. 2015;41(10):884\u201392.","journal-title":"Cancer Treat Rev"},{"key":"3600_CR7","doi-asserted-by":"crossref","unstructured":"X Y, C C, S C, Z Y, Sp B. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene. 2014;33(22). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23752196\/. Cited 2024 Dec 18.","DOI":"10.1038\/onc.2013.235"},{"issue":"6","key":"3600_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/14728222.2019.1615883","volume":"23","author":"ED Pope","year":"2019","unstructured":"Pope ED, Kimbrough EO, Vemireddy LP, Surapaneni PK, Copland JA, Mody K. Aberrant lipid metabolism as a therapeutic target in liver cancer. Expert Opin Ther Targets. 2019;23(6):473\u201383.","journal-title":"Expert Opin Ther Targets"},{"key":"3600_CR9","doi-asserted-by":"crossref","unstructured":"D ZDS, Jc de S, Tm P, B da SM, Rsr J, Sms B, et al. The impact of lipid metabolism on breast cancer: a review about its role in tumorigenesis and immune escape. Cell communication and signaling\u202f: CCS. 2023;21(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37370164\/. Cited 2024 Dec 18.","DOI":"10.1186\/s12964-023-01178-1"},{"key":"3600_CR10","doi-asserted-by":"crossref","unstructured":"M M, R C, F P, G M, N M, M P, et al. Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer. The Journal of experimental medicine. 2022;219(2). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34919143\/. Cited 2024 Dec 18.","DOI":"10.1084\/jem.20210564"},{"key":"3600_CR11","doi-asserted-by":"crossref","unstructured":"L Z, C Z, X Y, L L, J H, Y H, et al. Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1. Clinical and translational medicine. 2021;11(6). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34185414\/. Cited 2024 Dec 18.","DOI":"10.1002\/ctm2.449"},{"issue":"2","key":"3600_CR12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.7150\/thno.49384","volume":"11","author":"L Zhou","year":"2021","unstructured":"Zhou L, Song Z, Hu J, Liu L, Hou Y, Zhang X, et al. ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3. Theranostics. 2021;11(2):841\u201360.","journal-title":"Theranostics"},{"issue":"2","key":"3600_CR13","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3390\/ijms24021391","volume":"24","author":"M Zekovi\u0107","year":"2023","unstructured":"Zekovi\u0107 M, Bumba\u0161irevi\u0107 U, \u017divkovi\u0107 M, Pej\u010di\u0107 T. Alteration of lipid metabolism in prostate cancer: multifaceted oncologic implications. Int J Mol Sci. 2023;24(2):1391.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3600_CR14","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/onc.2017.385","volume":"37","author":"W Han","year":"2018","unstructured":"Han W, Gao S, Barrett D, Ahmed M, Han D, Macoska JA, et al. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. Oncogene. 2018;37(6):710\u201321.","journal-title":"Oncogene"},{"issue":"17","key":"3600_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174293","volume":"14","author":"A Siltari","year":"2022","unstructured":"Siltari A, Syv\u00e4l\u00e4 H, Lou YR, Gao Y, Murtola TJ. Role of lipids and lipid metabolism in prostate cancer progression and the tumor\u2019s immune environment. Cancers (Basel). 2022;14(17):4293.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"3600_CR16","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041404","volume":"15","author":"E Ikonen","year":"2023","unstructured":"Ikonen E, Olkkonen VM. Intracellular Cholesterol Trafficking. Cold Spring Harb Perspect Biol. 2023;15(8):a041404.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3600_CR17","doi-asserted-by":"crossref","unstructured":"A EK, W DV, M L, S A, J AM, A K, et al. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer. Cancer research. 2021;81(21). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34301759\/. Cited 2024 Dec 18.","DOI":"10.1158\/0008-5472.CAN-20-4028"},{"key":"3600_CR18","doi-asserted-by":"crossref","unstructured":"Y Y, Y B, Y H, Y Z, J C, L M, et al. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2018;24(4). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29167276\/. Cited 2024 Dec 18.","DOI":"10.1158\/1078-0432.CCR-17-2006"},{"issue":"20","key":"3600_CR19","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-11-0532","volume":"71","author":"C Cai","year":"2011","unstructured":"Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011;71(20):6503\u201313.","journal-title":"Cancer Res"},{"issue":"3","key":"3600_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1530\/JOE-11-0313","volume":"212","author":"BJ Clark","year":"2012","unstructured":"Clark BJ. The mammalian START domain protein family in lipid transport in health and disease. J Endocrinol. 2012;212(3):257\u201375.","journal-title":"J Endocrinol"},{"key":"3600_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.biochi.2013.09.015","volume":"96","author":"F Alpy","year":"2014","unstructured":"Alpy F, Tomasetto C. START ships lipids across interorganelle space. Biochimie. 2014;96:85\u201395.","journal-title":"Biochimie"},{"issue":"2","key":"3600_CR22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/cas.15449","volume":"114","author":"X Yue","year":"2023","unstructured":"Yue X, Kong Y, Zhang Y, Sun M, Liu S, Wu Z, et al. SREBF2-STARD4 axis confers sorafenib resistance in hepatocellular carcinoma by regulating mitochondrial cholesterol homeostasis. Cancer Sci. 2023;114(2):477\u201389.","journal-title":"Cancer Sci"},{"issue":"1","key":"3600_CR23","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1186\/s12967-024-05732-4","volume":"22","author":"G Li","year":"2024","unstructured":"Li G, Wu T, Li H, Wei C, Sun Y, Gao P, et al. Construction of a tumor mutational burden-derived LncRNA prognostic computational framework associated with therapy sensitivity in skin cutaneous melanoma. J Transl Med. 2024;22(1):966.","journal-title":"J Transl Med"},{"key":"3600_CR24","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.15203","volume":"11","author":"M Tan","year":"2023","unstructured":"Tan M, Lin X, Chen H, Ye W, Yi J, Li C, et al. Sterol regulatory element binding transcription factor 1 promotes proliferation and migration in head and neck squamous cell carcinoma. PeerJ. 2023;11:e15203.","journal-title":"PeerJ"},{"issue":"6","key":"3600_CR25","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.3892\/or.2020.7802","volume":"44","author":"M Zhang","year":"2020","unstructured":"Zhang M, Xiang Z, Wang F, Shan R, Li L, Chen J, et al. Stard4 promotes breast cancer cell malignancy. Oncol Rep. 2020;44(6):2487\u2013502.","journal-title":"Oncol Rep"},{"key":"3600_CR26","doi-asserted-by":"crossref","unstructured":"Li Q, Zeng K, Chen Q, Han C, Wang X, Li B, et al. Atractylenolide I inhibits angiogenesis and reverses sunitinib resistance in clear cell renal cell carcinoma through ATP6V0D2-mediated autophagic degradation of EPAS1\/HIF2\u03b1. Autophagy. 2025;21:619\u201338.","DOI":"10.1080\/15548627.2024.2421699"},{"issue":"2","key":"3600_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrm3270","volume":"13","author":"C Hetz","year":"2012","unstructured":"Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 2012;13(2):89\u2013102.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"3600_CR28","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1016\/j.bbamcr.2013.06.028","volume":"1833","author":"R Sano","year":"2013","unstructured":"Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta. 2013;1833(12):3460\u201370.","journal-title":"Biochim Biophys Acta"},{"issue":"2\u20133","key":"3600_CR29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10555-013-9474-0","volume":"33","author":"Z Culig","year":"2014","unstructured":"Culig Z, Santer FR. Androgen receptor signaling in prostate cancer. Cancer Metastasis Rev. 2014;33(2\u20133):413\u201327.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"3600_CR30","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41467-018-02863-3","volume":"9","author":"S Zhu","year":"2018","unstructured":"Zhu S, Zhao D, Yan L, Jiang W, Kim JS, Gu B, et al. BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1. Nat Commun. 2018;9(1):500.","journal-title":"Nat Commun"},{"issue":"1","key":"3600_CR31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/cancers12010062","volume":"12","author":"N Antoniou","year":"2019","unstructured":"Antoniou N, Lagopati N, Balourdas DI, Nikolaou M, Papalampros A, Vasileiou PVS, et al. The Role of E3, E4 Ubiquitin Ligase (UBE4B) in Human Pathologies. Cancers (Basel). 2019;12(1):62.","journal-title":"Cancers (Basel)"},{"issue":"23","key":"3600_CR32","first-page":"9632","volume":"14","author":"X Shao","year":"2022","unstructured":"Shao X, Zhu J, Shi Y, Fang H, Chen J, Zhang Y, et al. Upregulated UBE4B expression correlates with poor prognosis and tumor immune infiltration in hepatocellular carcinoma. Aging (Albany NY). 2022;14(23):9632\u201346.","journal-title":"Aging (Albany NY)"},{"key":"3600_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.153762","volume":"232","author":"S Wu","year":"2022","unstructured":"Wu S, Xie L, Cheng S, Fan Z, Sang H, Li Q. Ube4b promotes the development of lung adenocarcinoma by enhancing proliferation, migration and glycolysis via PP2A\/AKT signaling. Pathol Res Pract. 2022;232:153762.","journal-title":"Pathol Res Pract"},{"key":"3600_CR34","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.2147\/OTT.S196132","volume":"12","author":"C Weng","year":"2019","unstructured":"Weng C, Chen Y, Wu Y, Liu X, Mao H, Fang X, et al. Silencing UBE4B induces nasopharyngeal carcinoma apoptosis through the activation of caspase3 and p53. Onco Targets Ther. 2019;12:2553\u201361.","journal-title":"Onco Targets Ther"},{"key":"3600_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2017.04.038","volume":"401","author":"B Wang","year":"2017","unstructured":"Wang B, Wu H, Chai C, Lewis J, Pichiorri F, Eisenstat DD, et al. Microrna-1301 suppresses tumor cell migration and invasion by targeting the p53\/UBE4B pathway in multiple human cancer cells. Cancer Lett. 2017;401:20\u201332.","journal-title":"Cancer Lett"},{"issue":"12","key":"3600_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008504","volume":"16","author":"S Mohanty","year":"2020","unstructured":"Mohanty S, Han T, Choi YB, Lavorgna A, Zhang J, Harhaj EW. The E3\/E4 ubiquitin conjugation factor UBE4B interacts with and ubiquitinates the HTLV-1 Tax oncoprotein to promote NF-\u03baB activation. PLoS Pathog. 2020;16(12):e1008504.","journal-title":"PLoS Pathog"},{"issue":"6","key":"3600_CR37","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1158\/1078-0432.CCR-15-1632","volume":"22","author":"T Wang","year":"2016","unstructured":"Wang T, Song W, Chen Y, Chen R, Liu Z, Wu L, et al. Flightless i homolog represses prostate cancer progression through targeting androgen receptor signaling. Clin Cancer Res. 2016;22(6):1531\u201344.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3600_CR38","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42(3):354\u201373.","journal-title":"Endocr Rev"},{"key":"3600_CR39","doi-asserted-by":"publisher","first-page":"13786","DOI":"10.1038\/s41598-019-50220-1","volume":"9","author":"F Handle","year":"2019","unstructured":"Handle F, Prekovic S, Helsen C, Van den Broeck T, Smeets E, Moris L, et al. Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. Sci Rep. 2019;9:13786.","journal-title":"Sci Rep"},{"issue":"4","key":"3600_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104056","volume":"25","author":"MJ Salji","year":"2022","unstructured":"Salji MJ, Blomme A, D\u00e4britz JHM, Repiscak P, Lilla S, Patel R, et al. Multi-omics & pathway analysis identify potential roles for tumor N-acetyl aspartate accumulation in murine models of castration-resistant prostate cancer. iScience. 2022;25(4):104056.","journal-title":"iScience"},{"issue":"8","key":"3600_CR41","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/carcin\/bgx058","volume":"38","author":"KH Stopsack","year":"2017","unstructured":"Stopsack KH, Gerke TA, Andr\u00e9n O, Andersson SO, Giovannucci EL, Mucci LA, et al. Cholesterol uptake and regulation in high-grade and lethal prostate cancers. Carcinogenesis. 2017;38(8):806\u201311.","journal-title":"Carcinogenesis"},{"issue":"21","key":"3600_CR42","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1091\/mbc.e11-04-0372","volume":"22","author":"B Mesmin","year":"2011","unstructured":"Mesmin B, Pipalia NH, Lund FW, Ramlall TF, Sokolov A, Eliezer D, et al. Stard4 abundance regulates sterol transport and sensing. Mol Biol Cell. 2011;22(21):4004\u201315.","journal-title":"Mol Biol Cell"},{"issue":"3","key":"3600_CR43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41580-018-0085-z","volume":"20","author":"JA Olzmann","year":"2019","unstructured":"Olzmann JA, Carvalho P. Dynamics and functions of lipid droplets. Nat Rev Mol Cell Biol. 2019;20(3):137\u201355.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"3600_CR44","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1158\/2159-8290.CD-14-1507","volume":"5","author":"B Qiu","year":"2015","unstructured":"Qiu B, Ackerman D, Sanchez DJ, Li B, Ochocki JD, Grazioli A, et al. HIF2\u03b1-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma. Cancer Discov. 2015;5(6):652\u201367.","journal-title":"Cancer Discov"},{"issue":"21","key":"3600_CR45","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1042\/CS20160339","volume":"130","author":"U Soffientini","year":"2016","unstructured":"Soffientini U, Graham A. Intracellular cholesterol transport proteins: roles in health and disease. Clin Sci Lond. 2016;130(21):1843\u201359.","journal-title":"Clin Sci Lond"},{"issue":"4","key":"3600_CR46","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.bbrc.2006.03.051","volume":"343","author":"S Yamada","year":"2006","unstructured":"Yamada S, Yamaguchi T, Hosoda A, Iwawaki T, Kohno K. Regulation of human STARD4 gene expression under endoplasmic reticulum stress. Biochem Biophys Res Commun. 2006;343(4):1079\u201385.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"3600_CR47","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.bbalip.2011.06.028","volume":"1811","author":"D Rodriguez-Agudo","year":"2011","unstructured":"Rodriguez-Agudo D, Calderon-Dominguez M, Ren S, Marques D, Redford K, Medina-Torres MA, et al. Subcellular localization and regulation of StarD4 protein in macrophages and fibroblasts. Biochim Biophys Acta. 2011;1811(10):597\u2013606.","journal-title":"Biochim Biophys Acta"},{"key":"3600_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.04.010","volume":"516","author":"Z Hou","year":"2021","unstructured":"Hou Z, Huang S, Li Z. Androgens in prostate cancer: a tale that never ends. Cancer Lett. 2021;516:1\u201312.","journal-title":"Cancer Lett"},{"issue":"20","key":"3600_CR49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2218229120","volume":"120","author":"R Singh","year":"2023","unstructured":"Singh R, Meng H, Shen T, Lumahan LEV, Nguyen S, Shen H, et al. TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2023;120(20):e2218229120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"3600_CR50","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccr.2009.02.021","volume":"15","author":"K Xu","year":"2009","unstructured":"Xu K, Shimelis H, Linn DE, Jiang R, Yang X, Sun F, et al. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell. 2009;15(4):270\u201382.","journal-title":"Cancer Cell"},{"issue":"4","key":"3600_CR51","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/pros.22763","volume":"74","author":"B Li","year":"2014","unstructured":"Li B, Lu W, Yang Q, Yu X, Matusik RJ, Chen Z. Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt\/mTOR pathways in prostate cancer. Prostate. 2014;74(4):421\u201332.","journal-title":"Prostate"},{"issue":"27","key":"3600_CR52","doi-asserted-by":"publisher","first-page":"22959","DOI":"10.1074\/jbc.M111.338350","volume":"287","author":"DE Linn","year":"2012","unstructured":"Linn DE, Yang X, Xie Y, Alfano A, Deshmukh D, Wang X, et al. Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-dependent recruitment of distinct ubiquitin E3 ligases. J Biol Chem. 2012;287(27):22959\u201368.","journal-title":"J Biol Chem"},{"issue":"5","key":"3600_CR53","first-page":"409","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409\u201336.","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"3600_CR54","doi-asserted-by":"publisher","first-page":"10104","DOI":"10.1093\/nar\/gkz790","volume":"47","author":"F Yuan","year":"2019","unstructured":"Yuan F, Hankey W, Wu D, Wang H, Somarelli J, Armstrong AJ, et al. Molecular determinants for enzalutamide-induced transcription in prostate cancer. Nucleic Acids Res. 2019;47(19):10104\u201314.","journal-title":"Nucleic Acids Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03600-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03600-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03600-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:01:53Z","timestamp":1765522913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03600-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3600"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03600-7","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the First Affiliated Hospital of Shihezi University (KJ2024-042\u201301). All animal experiments compliance with regulations of Animal Ethics Committees in the First Affiliated Hospital of Shihezi University (Document No. A2024-038\u201301).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"318"}}